| Note | |
| | |
| Entity | Neuroblastoma |
| Note | Neuroblastoma karyotypes frequently reveal the cytogenetic hallmarks of gene amplification, namely DMs or HSRs. Schwab (Schwab et al., 1983) and Kohl (Kohl et al., 1983) originally identified the MYC-related oncogene MYCN as the target of this amplification event. MYCN is located on the distal short arm of chromosome 2 (2p24), but in cells with MYCN amplification, the extra copies reside within these DMs or HSRs (Schwab et al., 1984). Additional genes may be coamplified with MYCN in a subset of cases (DDX1, NAG, ALK), but MYCN is the only gene that is consistently amplified from this locus. The magnitude of MYCN amplification varies, but it averages 100-200 copies per cell (range 5-500+ copies).
The overall prevalence of MYCN amplification is 18-20%. Amplification of MYCN is associated with advanced stages of disease, unfavorable biological features, and a poor outcome (Brodeur et al., 1984; Seeger et al., 1985), but it is also associated with poor outcome in otherwise favorable patient groups (such as infants, and patients with lower stages of disease), underscoring its biological importance (Seeger et al., 1985; Look et al., 1991; Tonini et al., 1997; Katzenstein et al., 1998; Bagatell et al., 2005; George et al., 2005; Schneiderman et al., 2008). Therefore, the status of the MYCN gene is routinely determined from neuroblastoma samples obtained at diagnosis to assist in therapy planning (Look et al., 1991; Schwab et al., 2004). Indeed, because of the dramatic degree of MYCN amplification and consequent overexpression in a subset of aggressive neuroblastomas, it should be an attractive therapeutic target (Pession and Tonelli, 2005; Bell et al., 2010).
Weiss and colleagues (Weiss et al., 1997) created a transgenic mouse model of neuroblastoma, with MYCN expression driven in adrenergic cells by the tyrosine hydroxylase promoter (TH-MYCN mouse). Genomic changes in neuroblastomas arising in TH-MYCN mice closely parallel the genomic changes found characteristically in human tumors (Hackett et al., 2003). Thus, the TH-MYCN mouse model appears to be a tractable model to study neuroblastoma development, progression and therapy (Chessler and Weiss, 2011). |
| | |
| | |
| Entity | Medulloblastoma |
| Note | MYCN amplification is less common in medulloblastoma, a neural brain tumor of childhood, but it is also associated with a worse clinical outcome (Pfister et al., 2009). However, recent evidence suggests that MYCN overexpression is much more common in medulloblastomas, compared to normal cerebellum (Swartling et al., 2010), and it may drive the initiation or progression of medulloblastomas independent of the sonic hedgehog (SHH) pathway. Indeed, MYCN amplification is found in both SHH-driven and non-SHH-driven medulloblastomas, but each subtype is associated with other genetic features, suggesting they represent genetically distinct subtypes with different prognoses (Korshunov et al., 2011). |
| | |
| | |
| Entity | Rhabdomyosarcoma (RMS) |
| Note | MYCN amplification also occurs in a subset of RMS, the most common pediatric soft tissue sarcoma, although it tends to be at a lower level (4-20 fold) than is found in neuroblastomas. Amplification is found predominantly in the alveolar subsest of RMS, and it is rarely found in the more common form, called embryonal RMS (Driman et al., 1994). However, MYCN expression is found in the vast majority of RMS tumors, regardless of histology, at least in primary tumors (Toffolatti et al., 2002). For this reason, Morgenstern and Anderson have suggested that it would be an attractive therapeutic target for this disease (Morgenstern and Anderson, 2006). |
| | |
| | |
| Entity | Wilms tumor |
| Note | Wilms tumor may occasionally show amplification of the MYCN protooncogene (Schaub et al., 2007). MYCN amplification is consistently associated with overexpression, at least at the mRNA level. Initially, MYCN amplification was associated almost exclusively with the unfavorable, anaplastic subset of Wilms tumors. However, Williams and colleagues (Williams et al., 2011) found focal gain of MYCN in a substantial number of both anaplastic and favorable histologies in a survey of over 400 tumors, suggesting that other genomic changes may account for differences in clinical behavior. |
| | |
| | |
| Entity | Other tumors (retinoblastoma, small cell lung cancer, glioblastoma multiforme) |
| Note | About 3-5% of primary retinoblastomas have MYCN amplification, whereas it is much more common (27%) in established retinoblastoma cell lines (Bowles et al., 2007; Kim et al., 2008). MYCN is amplified in 15-25% of small cell lung cancers, and it may be more common in tumors at relapse (Johnson et al., 1987; Johnson et al., 1992). MYCN amplification rarely occurs in other lung cancer histologies (Yokota et al., 1988). MYCN amplification occurs in a substantial number of glioblastoma multiformes (Hui et al., 2001; Hodgson et al., 2008), but it is rarely found in lower grade gliomas and astrocytomas. |
| | |
| Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. |
| Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC. |
| J Clin Oncol. 2005 Dec 1;23(34):8819-27. |
| PMID 16314642 |
| |
| MYCN oncoprotein targets and their therapeutic potential. |
| Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. |
| Cancer Lett. 2010 Jul 28;293(2):144-57. Epub 2010 Feb 13. (REVIEW) |
| PMID 20153925 |
| |
| Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. |
| Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, Gallie BL. |
| Genes Chromosomes Cancer. 2007 Feb;46(2):118-29. |
| PMID 17099872 |
| |
| Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. |
| Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. |
| Science. 1984 Jun 8;224(4653):1121-4. |
| PMID 6719137 |
| |
| Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. |
| Chesler L, Weiss WA. |
| Semin Cancer Biol. 2011 Oct;21(4):245-55. Epub 2011 Sep 21. (REVIEW) |
| PMID 21958944 |
| |
| MYCN gene amplification in rhabdomyosarcoma. |
| Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J. |
| Cancer. 1994 Apr 15;73(8):2231-7. |
| PMID 8156531 |
| |
| Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. |
| George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. |
| J Clin Oncol. 2005 Sep 20;23(27):6466-73. Epub 2005 Aug 22. |
| PMID 16116152 |
| |
| Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. |
| Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA. |
| Cancer Res. 2003 Sep 1;63(17):5266-73. |
| PMID 14500357 |
| |
| Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. |
| Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD. |
| Neuro Oncol. 2009 Oct;11(5):477-87. Epub 2009 Jan 12. |
| PMID 19139420 |
| |
| Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. |
| Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. |
| Lab Invest. 2001 May;81(5):717-23. |
| PMID 11351043 |
| |
| myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer. |
| Johnson BE, Brennan JF, Ihde DC, Gazdar AF. |
| J Natl Cancer Inst Monogr. 1992;(13):39-43. |
| PMID 1327035 |
| |
| Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. |
| Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL. |
| J Clin Oncol. 1998 Jun;16(6):2007-17. |
| PMID 9626197 |
| |
| N-myc amplification was rarely detected by fluorescence in situ hybridization in retinoblastoma. |
| Kim JH, Choi JM, Yu YS, Kim DH, Kim JH, Kim KW. |
| Hum Pathol. 2008 Aug;39(8):1172-5. Epub 2008 Jun 5. |
| PMID 18538370 |
| |
| Transposition and amplification of oncogene-related sequences in human neuroblastomas. |
| Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, Alt FW. |
| Cell. 1983 Dec;35(2 Pt 1):359-67. |
| PMID 6197179 |
| |
| Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. |
| Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DT, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, von Deimling A, Scheurlen W, Kulozik AE, Clifford SC, Peter Collins V, Westermann F, Taylor MD, Lichter P, Pfister SM. |
| Acta Neuropathol. 2012 Apr;123(4):515-27. Epub 2011 Dec 9. |
| PMID 22160402 |
| |
| Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. |
| Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM. |
| J Clin Oncol. 1991 Apr;9(4):581-91. |
| PMID 2066755 |
| |
| MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma. |
| Morgenstern DA, Anderson J. |
| Expert Rev Anticancer Ther. 2006 Feb;6(2):217-24. (REVIEW) |
| PMID 16445374 |
| |
| The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. |
| Pession A, Tonelli R. |
| Curr Cancer Drug Targets. 2005 Jun;5(4):273-83. (REVIEW) |
| PMID 15975048 |
| |
| Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. |
| Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A. |
| J Clin Oncol. 2009 Apr 1;27(10):1627-36. Epub 2009 Mar 2. |
| PMID 19255330 |
| |
| Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. |
| Schaub R, Burger A, Bausch D, Niggli FK, Schafer BW, Betts DR. |
| Cancer Genet Cytogenet. 2007 Jan 1;172(1):61-5. |
| PMID 17175381 |
| |
| Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. |
| Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. |
| J Clin Oncol. 2008 Feb 20;26(6):913-8. |
| PMID 18281664 |
| |
| Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. |
| Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J. |
| Nature. 1983 Sep 15-21;305(5931):245-8. |
| PMID 6888561 |
| |
| MYCN in neuronal tumours. |
| Schwab M. |
| Cancer Lett. 2004 Feb 20;204(2):179-87. (REVIEW) |
| PMID 15013217 |
| |
| Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. |
| Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. |
| N Engl J Med. 1985 Oct 31;313(18):1111-6. |
| PMID 4047115 |
| |
| Pleiotropic role for MYCN in medulloblastoma. |
| Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA, Chesler L. |
| Genes Dev. 2010 May 15;24(10):1059-72. |
| PMID 20478998 |
| |
| MYCN expression in human rhabdomyosarcoma cell lines and tumour samples. |
| Toffolatti L, Frascella E, Ninfo V, Gambini C, Forni M, Carli M, Rosolen A. |
| J Pathol. 2002 Apr;196(4):450-8. |
| PMID 11920742 |
| |
| MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. |
| Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Pession A, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P, De Bernardi B. |
| J Clin Oncol. 1997 Jan;15(1):85-93. |
| PMID 8996128 |
| |
| Targeted expression of MYCN causes neuroblastoma in transgenic mice. |
| Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. |
| EMBO J. 1997 Jun 2;16(11):2985-95. |
| PMID 9214616 |
| |
| Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. |
| Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K. |
| Genes Chromosomes Cancer. 2011 Dec;50(12):982-95. doi: 10.1002/gcc.20907. Epub 2011 Aug 31. |
| PMID 21882282 |
| |
| Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes. |
| Yokota J, Wada M, Yoshida T, Noguchi M, Terasaki T, Shimosato Y, Sugimura T, Terada M. |
| Oncogene. 1988 Jun;2(6):607-11. |
| PMID 2838790 |
| |
